TAS120

Research use only, not for human use.

TAS-120 is a novel potent and highly selective FGFR inhibitor used for antitumor treatment.

TAS-120 is a novel potent and highly selective FGFR inhibitor used for antitumor treatment.(In Vitro):Futibatinib (TAS-120) covalently binds to a highly conserved P-loop cysteine residue in the ATP pocket of FGFR.(In Vivo):Futibatinib (TAS-120) (3, 30, 100 mg/kg/day, p.o.) exerts an anti-tumor effect in mice. Futibatinib (TAS-120) shows anti-tumor effect by administering at moderate intervals, such as intermittent administration of every other day dosing and 2 times/week, and reducing the sustained elevation and weight suppression blood phosphorus level, and take a antitumor effective as daily administration.

——

——

Futibatinib | FGFR-IN-1

Angiogenesis

FGFR

FGFR

Cancer

Solid tumours

1448169-71-8

418.45

C22H22N6O3

>98% (HPLC)

DMSO:≥ 29 mg/mL (69.30 mM)

COc1cc(OC)cc(c1)C#Cc1nn([C@H]2CCN(C2)C(=O)C=C)c2ncnc(N)c12

1-[(3S)-3-[4-amino-3-[2-(35-dimethoxyphenyl)ethynyl]-1H-pyrazolo[34-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one

(-20℃)

With Ice Pack

≥ 2 years